{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:45:06Z","timestamp":1793663106397,"version":"4.5.1"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"\n Importance<\/jats:title>\n A clear and comprehensive understanding of risks associated with psychedelic-assisted therapy is necessary as investigators extend its application to new populations and indications.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess adverse events (AEs) associated with classic psychedelics, particularly serious AEs (SAEs) and nonserious AEs (NSAEs) requiring medical or psychiatric evaluation.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n The search for potentially eligible studies was conducted in the Scopus, MEDLINE, PsycINFO, and Web of Science databases from inception through February 8, 2024.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Two independent reviewers screened articles of classic psychedelics (lysergic acid diethylamide [LSD], psilocybin, dimethyltryptamine [DMT], and 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT]) involving administration in clinical or research contexts.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n AE data were extracted and synthesized by 2 reviewers and were used for random-effects meta-analysis of AE frequency and heterogeneity. Risk of bias assessment focused on AE ascertainment (eg, systematic assessment and quality of follow-up).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n A hybrid approach was used for capture of all reported AEs following high-dose classic psychedelic exposure and confirmatory capture of AEs of special interest, including suicidality, psychotic disorder, manic symptoms, cardiovascular events, and hallucinogen persisting perception disorder. AEs were stratified by timescale and study population type. Forest plots of common AEs were generated, and the proportions of participants affected by SAEs or NSAEs requiring medical intervention were summarized descriptively.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 214 unique studies were included, of which 114 (53.3%) reported analyzable AE data for 3504 total participants. SAEs were reported for no healthy participants and for approximately 4% of participants with preexisting neuropsychiatric disorders; among these SAEs were worsening depression, suicidal behavior, psychosis, and convulsive episodes. NSAEs requiring medical intervention (eg, paranoia, headache) were similarly rare. In contemporary research settings, there were no reports of deaths by suicide, persistent psychotic disorders, or hallucinogen persisting perception disorders following administration of high-dose classic psychedelics. However, there was significant heterogeneity in the quality of AE monitoring and reporting. Of 68 analyzed studies published since 2005, only 16 (23.5%) described systematic approaches to AE assessment, and 20 studies (29.4%) reported all AEs, as opposed to only adverse drug reactions. Meta-analyses of prevalence for common AEs (eg, headache, anxiety, nausea, fatigue, and dizziness) yielded comparable results for psilocybin and LSD.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this systematic review and meta-analysis, classic psychedelics were generally well tolerated in clinical or research settings according to the existing literature, although SAEs did occur. These results provide estimates of common AE frequencies and indicate that certain catastrophic events reported in recreational or nonclinical contexts have yet to be reported in contemporary trial participants. Careful, ongoing, and improved pharmacovigilance is required to understand the risk and benefit profiles of these substances and to communicate such risks to prospective study participants and the public.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2024.2546","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T11:09:24Z","timestamp":1725448164000},"page":"1225","source":"Crossref","is-referenced-by-count":167,"title":["Adverse Events in Studies of Classic Psychedelics"],"prefix":"10.1001","volume":"81","author":[{"given":"Jared T.","family":"Hinkle","sequence":"first","affiliation":[{"name":"Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Graziosi","sequence":"additional","affiliation":[{"name":"Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Clinical Psychology, Hofstra University, Hempstead, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep M.","family":"Nayak","sequence":"additional","affiliation":[{"name":"Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Yaden","sequence":"additional","affiliation":[{"name":"Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"yoi240055r1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","article-title":"Studying harms is key to improving psychedelic-assisted therapy-participants call for changes to research landscape.","volume":"80","author":"McNamee","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"yoi240055r2","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future.","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"yoi240055r3","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3389\/fpsyg.2020.01681","article-title":"Psychedelic research and the need for transparency: polishing Alice\u2019s looking glass.","volume":"11","author":"Petranker","year":"2020","journal-title":"Frontiers Psychol"},{"issue":"10","key":"yoi240055r4","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/02698811221116926","article-title":"Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review.","volume":"36","author":"Breeksema","year":"2022","journal-title":"J Psychopharmacol"},{"key":"yoi240055r5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/00005053-196001000-00005","article-title":"Lysergic acid diethylamide: side effects and complications.","volume":"130","author":"Cohen","year":"1960","journal-title":"J Nerv Ment Dis"},{"issue":"543","key":"yoi240055r6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1192\/bjp.118.543.229","article-title":"Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom.","volume":"118","author":"Malleson","year":"1971","journal-title":"Br J Psychiatry"},{"issue":"2","key":"yoi240055r7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0957154X16629902","article-title":"Neurotoxicity and LSD treatment: a follow-up study of 151 patients in Denmark.","volume":"27","author":"Larsen","year":"2016","journal-title":"Hist Psychiatry"},{"issue":"11","key":"yoi240055r8","first-page":"53","article-title":"Complications of therapy with lysergide.","volume":"101","author":"Denson","year":"1969","journal-title":"Can Med Assoc J"},{"issue":"23","key":"yoi240055r9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJM196512022732302","article-title":"Untoward reactions to lysergic acid diethylamide (LSD) resulting in hospitalization.","volume":"273","author":"Frosch","year":"1965","journal-title":"N Engl J Med"},{"issue":"10","key":"yoi240055r10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/00005053-198410000-00001","article-title":"Adverse reactions to psychedelic drugs. a review of the literature.","volume":"172","author":"Strassman","year":"1984","journal-title":"J Nerv Ment Dis"},{"issue":"6","key":"yoi240055r11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety.","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"issue":"2","key":"yoi240055r12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects.","volume":"4","author":"Olson","year":"2020","journal-title":"ACS Pharmacol Translational Sci"},{"issue":"2","key":"yoi240055r13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects.","volume":"4","author":"Yaden","year":"2020","journal-title":"ACS Pharmacol Translational Sci"},{"issue":"71","key":"yoi240055r14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"yoi240055r16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial.","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evidence Based Ment Health"},{"key":"yoi240055r18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.760671","article-title":"A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-N, N-dimethyltryptamine formulation (GH001) in healthy volunteers.","volume":"12","author":"Reckweg","year":"2021","journal-title":"Front Pharmacol"},{"key":"yoi240055r19","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1133414","article-title":"A phase 1\/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression.","volume":"14","author":"Reckweg","year":"2023","journal-title":"Front Psychiatry"},{"issue":"3","key":"yoi240055r20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase ii study.","volume":"93","author":"Holze","year":"2023","journal-title":"Biol Psychiatry"},{"issue":"10","key":"yoi240055r21","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","article-title":"Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder.","volume":"47","author":"D\u2019Souza","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"23","key":"yoi240055r22","first-page":"1200","article-title":"The use of lysergic acid diethylamide (LSD) in psychotherapy.","volume":"91","author":"Baker","year":"1964","journal-title":"Can Med Assoc J"},{"issue":"10","key":"yoi240055r23","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","article-title":"A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics.","volume":"125","author":"Hollister","year":"1969","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi240055r24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.15288\/qjsa.1967.28.295","article-title":"Treatment of alcoholism with lysergide.","volume":"28","author":"Van Dusen","year":"1967","journal-title":"Q J Stud Alcohol"},{"issue":"5","key":"yoi240055r25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/archpsyc.1966.01730170002002","article-title":"Prolonged adverse reactions to LSD in psychotic subjects.","volume":"15","author":"Fink","year":"1966","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"yoi240055r26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict. a controlled study.","volume":"28","author":"Savage","year":"1973","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"yoi240055r27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Ment Dis"},{"issue":"18","key":"yoi240055r28","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"yoi240055r29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial.","volume":"37","author":"Sloshower","year":"2023","journal-title":"J Psychopharmacol"},{"key":"yoi240055r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"yoi240055r31","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1215972","article-title":"Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder.","volume":"14","author":"Heinzerling","year":"2023","journal-title":"Front Psychiatry"},{"issue":"7","key":"yoi240055r32","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/cncr.35010","article-title":"Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.","volume":"130","author":"Agrawal","year":"2024","journal-title":"Cancer"},{"issue":"12","key":"yoi240055r33","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"1","key":"yoi240055r34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"yoi240055r35","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"3","key":"yoi240055r36","first-page":"282","article-title":"Follow-up evaluation of LSD psychotherapy of inpatients.","volume":"10","author":"Hausner","year":"1968","journal-title":"Activitas Nerv Super (Praha)"},{"issue":"1","key":"yoi240055r37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.drugalcdep.2010.09.006","article-title":"Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire.","volume":"114","author":"Baggott","year":"2011","journal-title":"Drug Alcohol Dependence"},{"issue":"4","key":"yoi240055r38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1001\/archpsyc.57.4.311","article-title":"Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.","volume":"57","author":"Khan","year":"2000","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"yoi240055r39","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1176\/appi.ajp.160.4.790","article-title":"Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports.","volume":"160","author":"Khan","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"1","key":"yoi240055r40","first-page":"6","article-title":"Suicide risk analysis among patients assigned to psychotropics and placebo.","volume":"39","author":"Khan","year":"2006","journal-title":"Psychopharmacol Bull"},{"issue":"9","key":"yoi240055r41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002127","article-title":"Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review.","volume":"13","author":"Golder","year":"2016","journal-title":"PLoS Med"},{"issue":"3","key":"yoi240055r43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.psc.2016.04.005","article-title":"Adverse effects of psychotropic medications: a call to action.","volume":"39","author":"Mago","year":"2016","journal-title":"Psychiatr Clin North Am"},{"issue":"12","key":"yoi240055r44","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences.","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"4","key":"yoi240055r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5960","article-title":"Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis.","volume":"7","author":"Yerubandi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"yoi240055r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115880","article-title":"Safety and risk assessment of psychedelic psychotherapy: a meta-analysis and systematic review.","volume":"335","author":"Romeo","year":"2024","journal-title":"Psychiatry Res"},{"issue":"1","key":"yoi240055r47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/02698811231215420","article-title":"Older adults in psychedelic-assisted therapy trials: a systematic review.","volume":"38","author":"Bouchet","year":"2024","journal-title":"J Psychopharmacol"},{"key":"yoi240055r15","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Peryer","year":"2023"},{"key":"yoi240055r17","unstructured":"Wells? GA, Shea? B, O\u2019Connell? D, . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute. Accessed August 27, 2023. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"yoi240055r42","unstructured":"US Food and Drug Administration. Psychedelic drugs: considerations for clinical investigations. guidance for industry. Accessed August 1, 2024. https:\/\/www.fda.gov\/media\/169694\/download"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2822968\/jamapsychiatry_hinkle_2024_oi_240055_1733254036.00757.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:01:29Z","timestamp":1733310089000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2822968"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.2546","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}